Roles of LPA in ovarian cancer development and progression

Future Oncology

Volumn 5, Issue 10, 2009, Pages 1659-1673

  Pua, Tarah L ^a   Wang, Feng Qiang ^b   Fishman, David A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

LPA; Lysophosphatidic acid; Ovarian cancer

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AUTOTAXIN; CYCLOOXYGENASE 2; G PROTEIN COUPLED RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B KINASE; INTERSTITIAL COLLAGENASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; MATRILYSIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PROTEINASE; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 75149175293     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.120     Document Type: Review

References (141)

1. Fang X, Schummer M, Mao M et al.: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 1582(1-3), 257-264 (2002).
2. Tanyi JL, Morris AJ, Wolf JK et al.: The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res. 63(5), 1073-1082 (2003).
3. Sano T, Baker D, Virag T et al.: Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277(24), 21197-21206 (2002).
4. Xu Y, Shen Z, Wiper DW et al.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280(8), 719-723 (1998).
5. Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y: Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. NY Acad. Sci. 905, 242-259 (2000).
6. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ: Direct quantitative ana lysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal. Biochem. 292(2), 287-295 (2001).
7. An S, Bleu T, Hallmark OG, Goetzl EJ: Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273(14), 7906-7910 (1998).
8. Bandoh K, Aoki J, Hosono H et al.: Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274(39), 27776-27785 (1999).
9. Hecht JH, Weiner JA, Post SR, Chun J: Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135(4), 1071-1083 (1996).
10. Kotarsky K, Boketoft A, Bristulf J et al.: Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 318(2), 619-628 (2006).
11. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J: GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281(33), 23589-23597 (2006).
12. Noguchi K, Ishii S, Shimizu T: Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278(28), 25600-25606 (2003).
13. Yanagida K, Masago K, Nakanishi H et al.: Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol. Chem. 284(26), 17731-17741 (2009).
14. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N: The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 363(3), 861-866 (2007).
15. Murakami M, Shiraishi A, Tabata K, Fujita N: Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 371(4), 707-712 (2008).
16. Sanchez T, Hla T: Structural and functional characteristics of S1P receptors. J. Cell Biochem. 92(5), 913-922 (2004).
17. Spiegel S, Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4(5), 397-407 (2003).
18. McIntyre TM, Pontsler AV, Silva AR et al.: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl Acad. Sci. USA 100(1), 131-136 (2003).
19. Zhang C, Baker DL, Yasuda S et al.: Lysophosphatidic acid induces neointima formation through PPARγ activation. J. Exp. Med. 199(6), 763-774 (2004).
20. Aoki J, Taira A, Takanezawa Y et al.: Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. 277(50), 48737-48744 (2002).
21. Mahadevappa VG, Holub BJ: The molecular species composition of individual diacyl phospholipids in human platelets. Biochim. Biophys. Acta 713(1), 73-79 (1982).
22. Myher JJ, Kuksis A, Pind S: Molecular species of glycerophospholipids and sphingomyelins of human plasma: comparison to red blood cells. Lipids 24(5), 408-418 (1989).
23. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K: Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 478(1-2), 159-165 (2000).
24. Baker DL, Fujiwara Y, Pigg KR et al.: Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem. 281(32), 22786-22793 (2006).
25. Six DA, Dennis EA: The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta 1488(1-2), 1-19 (2000).
26. Pebay A, Bonder CS, Pitson SM: Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat. 84(3-4), 83-97 (2007).
27. Ginestra A, Miceli D, Dolo V, Romano FM, Vittorelli ML: Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res. 19(4C), 3439-3445 (1999).
28. Ren J, Xiao YJ, Singh LS et al.: Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 66(6), 3006-3014 (2006).
29. Song Y, Wilkins P, Hu W et al.: Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem. J. 406(3), 427-436 (2007).
30. Murata J, Lee HY, Clair T et al.: cDNA cloning of the human tumor motilitystimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 269(48), 30479-30484 (1994).
31. Nam SW, Clair T, Kim YS et al.: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61(18), 6938-6944 (2001).
32. Yang SY, Lee J, Park CG et al.: Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 19(7), 603-608 (2002).
33. Tokumura A, Majima E, Kariya Y et al.: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277(42), 39436-39442 (2002).
34. Clair T, Aoki J, Koh E et al.: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63(17), 5446-5453 (2003).
35. Gijsbers R, Aoki J, Arai H, Bollen M: The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett. 538(1-3), 60-64 (2003).
36. Goetzl EJ, Dolezalova H, Kong Y et al.: Distinctive expression and functions of the type 4 endothelial differentiation geneencoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59(20), 5370-5375 (1999).
37. Goetzl EJ, An S: A subfamily of G proteincoupled cellular receptors for lysophospholipids and lysosphingolipids. Adv. Exp. Med. Biol. 469, 259-264 (1999).
38. Smicun Y, Reierstad S, Wang FQ, Lee C, Fishman DA: S1P regulation of ovarian carcinoma invasiveness. Gynecol. Oncol. 103(3), 952-959 (2006).
39. Croset M, Brossard N, Polette A, Lagarde M: Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem. J. 345(Pt 1), 61-67 (2000).
40. Sciorra VA, Morris AJ: Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim. Biophys. Acta 1582(1-3), 45-51 (2002).
41. Schmidt A, Wolde M, Thiele C et al.: Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature 401(6749), 133-141 (1999).
42. Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3(8), 582-591 (2003).
43. Stassar MJ, Devitt G, Brosius M et al.: Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br. J. Cancer 85(9), 1372-1382 (2001).
44. Umezu-Goto M, Tanyi J, Lahad J et al.: Lysophosphatidic acid production and action: validated targets in cancer? J. Cell Biochem. 92(6), 1115-1140 (2004).
45. Schaner ME, Ross DT, Ciaravino G et al.: Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 14(11), 4376-4386 (2003).
46. van Meeteren LA, Ruurs P, Christodoulou E et al.: Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J. Biol. Chem. 280(22), 21155-21161 (2005).
47. Hooks SB, Santos WL, Im DS, Heise CE, Macdonald TL, Lynch KR: Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J. Biol. Chem. 276(7), 4611-4621 (2001).
48. Imai A, Furui T, Tamaya T, Mills GB: A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J. Clin. Endocrinol. Metab. 85(9), 3370-3375 (2000).
49. Brindley DN, Waggoner DW: Mammalian lipid phosphate phosphohydrolases. J. Biol. Chem. 273(38), 24281-24284 (1998).
50. Tanyi JL, Hasegawa Y, Lapushin R et al.: Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin. Cancer Res. 9(10 Pt 1), 3534-3545 (2003).
51. Yue J, Yokoyama K, Balazs L et al.: Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell Signal. 16(3), 385-399 (2004).
52. Brindley DN: Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J. Cell Biochem. 92(5), 900-912 (2004).
53. Pyne S, Long JS, Ktistakis NT, Pyne NJ: Lipid phosphate phosphatases and lipid phosphate signalling. Biochem. Soc. Trans. 33(Pt 6), 1370-1374 (2005).
54. Long J, Darroch P, Wan KF et al.: Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine 1-phosphate pools. Biochem. J. 391(Pt 1), 25-32 (2005).
55. Long JS, Yokoyama K, Tigyi G, Pyne NJ, Pyne S: Lipid phosphate phosphatase-1 regulates lysophosphatidic acid- and plateletderived-growth- factor-induced cell migration. Biochem. J. 394(Pt 2), 495-500 (2006).
56. Shano S, Hatanaka K, Ninose S, Moriyama R, Tsujiuchi T, Fukushima N: A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim. Biophys. Acta 1783(5), 748-759 (2007).
57. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S: Protein kinase C α-CARMA3 signaling axis links Ras to NF-κB for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 27(9), 1273-1280 (2008).
58. Lee Z, Cheng CT, Zhang H et al.: Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell 19(12), 5435-5445 (2008).
59. Haseruck N, Erl W, Pandey D et al.: The plaque lipid lysophosphatidic acid stimulates platelet activation and plateletmonocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 103(7), 2585-2592 (2004).
60. Retzer M, Essler M: Lysophosphatidic acid-induced platelet shape change proceeds via Rho/Rho kinase-mediated myosin light-chain and moesin phosphorylation. Cell Signal. 12(9-10), 645-648 (2000).
61. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res. 6(6), 2482-2491 (2000).
62. Furui T, LaPushin R, Mao M et al.: Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer Res. 5(12), 4308-4318 (1999).
63. Sengupta S, Kim KS, Berk MP et al.: Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26(20), 2894-2901 (2007).
64. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH: Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59(1), 45-54 (1989).
65. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J: Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl Acad. Sci. USA 97(24), 13384-13389 (2000).
66. Hama K, Aoki J, Fukaya M et al.: Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J. Biol. Chem. 279(17), 17634-17639 (2004).
67. Contos JJ, Ishii I, Fukushima N et al.: Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22(19), 6921-6929 (2002).
68. Ye X, Hama K, Contos JJ et al.: LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435(7038), 104-108 (2005).
69. Dey SK, Lim H, Das SK et al.: Molecular cues to implantation. Endocr. Rev. 25(3), 341-373 (2004).
70. Paria BC, Reese J, Das SK, Dey SK: Deciphering the cross-talk of implantation: advances and challenges. Science 296(5576), 2185-2188 (2002).
71. Lim H, Gupta RA, Ma WG et al.: Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARd. Genes Dev. 13(12), 1561-1574 (1999).
72. Song H, Lim H, Paria BC et al.: Cytosolic phospholipase A2a is crucial [correction of A2α deficiency is crucial] for 'on-time' embryo implantation that directs subsequent development. Development 129(12), 2879-2889 (2002).
73. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS: Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 65(6), 2234-2242 (2005).
74. Jeong KJ, Park SY, Seo JH et al.: Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp. Mol. Med. 40(6), 607-616 (2008).
75. Oyesanya RA, Lee ZP, Wu J et al.: Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J. 22(8), 2639-2651 (2008).
76. Sengupta S, Xiao YJ, Xu Y: A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J. 17(11), 1570-1572 (2003).
77. Xu J, Lai YJ, Lin WC, Lin FT: TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J. Biol. Chem. 279(11), 10459-10468 (2004).
78. Shida D, Kitayama J, Yamaguchi H et al.: Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63(7), 1706-1711 (2003).
79. Yu S, Murph MM, Lu Y et al.: Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl Cancer Inst. 100(22), 1630-1642 (2008).
80. Baker DL, Morrison P, Miller B et al.: Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287(23), 3081-3082 (2002).
81. Xu Y, Gaudette DC, Boynton JD et al.: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1(10), 1223-1232 (1995).
82. Xiao YJ, Schwartz B, Washington M et al.: Electrospray ionization mass spectrometry ana lysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal. Biochem. 290(2), 302-313 (2001).
83. Kim KS, Sengupta S, Berk M et al.: Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 66(16), 7983-7990 (2006).
84. Quintero M, Mackenzie N, Brennan PA: Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur. J. Surg. Oncol. 30(5), 465-468 (2004).
85. Hu YL, Tee MK, Goetzl EJ et al.: Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl Cancer Inst. 93(10), 762-768 (2001).
86. Ivarsson K, Runesson E, Sundfeldt K et al.: The chemotactic cytokine interleukin-8 - a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol. Oncol. 71(3), 420-423 (1998).
87. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997).
88. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ: Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 23(1), 122-129 (2004).
89. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6(4), 373-378 (1999).
90. So J, Wang FQ, Navari J, Schreher J, Fishman DA: LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol. Oncol. 97(3), 870-878 (2005).
91. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2(1), 38-47 (2002).
92. Lee J, Park SY, Lee EK et al.: Activation of hypoxia-inducible factor-1α is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin. Cancer Res. 12(21), 6351-6358 (2006).
93. Park SY, Jeong KJ, Lee J et al.: Hypoxia enhances LPA-induced HIF-1α and VEGF expression: their inhibition by resveratrol. Cancer Lett. 258(1), 63-69 (2007).
94. Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD: Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol. Cancer Res. 6(3), 352-363 (2008).
95. Fang X, Yu S, Bast RC et al.: Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem. 279(10), 9653-9661 (2004).
96. Schwartz BM, Hong G, Morrison BH et al.: Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol. Oncol. 81(2), 291-300 (2001).
97. So J, Navari J, Wang FQ, Fishman DA: Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol. Oncol. 95(2), 314-322 (2004).
98. Baggiolini M, Walz A, Kunkel SL: Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84(4), 1045-1049 (1989).
99. Gil OD, Lee C, Ariztia EV et al.: Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner. Gynecol. Oncol. 108(2), 361-369 (2008).
100. Murthi P, Barker G, Nowell CJ et al.: Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol. Oncol. 92(1), 80-88 (2004).
101. Schmalfeldt B, Prechtel D, Harting K et al.: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7(8), 2396-2404 (2001).
102. Li H, Ye X, Mahanivong C, Bian D, Chun J, Huang S: Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J. Biol. Chem. 280(11), 10564-10571 (2005).
103. Sun J, Lin X: β-arrestin 2 is required for lysophosphatidic acid-induced NF-κB activation. Proc. Natl Acad. Sci. USA 105(44), 17085-17090 (2008).
104. Yamaoka S, Courtois G, Bessia C et al.: Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93(7), 1231-1240 (1998).
105. Sommer K, Guo B, Pomerantz JL et al.: Phosphorylation of the CARMA1 linker controls NF-κB activation. Immunity 23(6), 561-574 (2005).
106. Sun W, Li H, Yu Y et al.: MEKK3 is required for lysophosphatidic acid-induced NF-κB activation. Cell. Signal. 21(10), 1488-1494 (2009).
107. Overall CM, Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2(9), 657-672 (2002).
108. Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS: Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through β1 integrin. Cancer Res. 59(7), 1635-1641 (1999).
109. Davidson B, Goldberg I, Gotlieb WH et al.: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis 17(10), 799-808 (1999).
110. Huang S, Van Arsdall M, Tedjarati S et al.: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl Cancer Inst. 94(15), 1134-1142 (2002).
111. Fishman DA, Bafetti LM, Stack MS: Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16(3), 150-159 (1996).
112. Fishman DA, Liu Y, Ellerbroek SM, Stack MS: Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61(7), 3194-3199 (2001).
113. Sakai T, de la Pena JM, Mosher DF: Synergism among lysophosphatidic acid, β1A integrins, and epidermal growth factor or platelet-derived growth factor in mediation of cell migration. J. Biol. Chem. 274(22), 15480-15486 (1999).
114. Sakai T, Peyruchaud O, Fassler R, Mosher DF: Restoration of β1A integrins is required for lysophosphatidic acid-induced migration of b1-null mouse fibroblastic cells. J. Biol. Chem. 273(31), 19378-19382 (1998).
115. Wang FQ, So J, Reierstad S, Fishman DA: Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int. J. Cancer 118(4), 879-888 (2006).
116. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM: Matrilysin in early stage intestinal tumorigenesis. APMIS 107(1), 102-110 (1999).
117. Masaki T, Matsuoka H, Sugiyama M et al.: Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br. J. Cancer 84(10), 1317-1321 (2001).
118. Wang FQ, Smicun Y, Calluzzo N, Fishman DA: Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol. Cancer Res. 4(11), 831-841 (2006).
119. Van Leeuwen FN, Olivo C, Grivell S, Giepmans BN, Collard JG, Moolenaar WH: Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J. Biol. Chem. 278(1), 400-406 (2003).
120. Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 420(6916), 629-635 (2002).
121. Kranenburg O, Poland M, van Horck FP, Drechsel D, Hall A, Moolenaar WH: Activation of RhoA by lysophosphatidic acid and Ga12/13 subunits in neuronal cells: induction of neurite retraction. Mol. Biol. Cell 10(6), 1851-1857 (1999).
122. Bian D, Su S, Mahanivong C et al.: Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res. 64(12), 4209-4217 (2004).
123. Sutphen R, Xu Y, Wilbanks GD et al.: Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13(7), 1185-1191 (2004).
124. Chen X, Yang XY, Wang ND et al.: Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand. J. Clin. Lab. Invest. 63(7-8), 497-503 (2003).
125. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A: Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J. Lipid Res. 43(12), 2049-2055 (2002).
126. Cerutis DR, Dreyer AC, Vierra MJ et al.: Lysophosphatidic acid modulates the healing responses of human periodontal ligament fibroblasts and enhances the actions of platelet-derived growth factor. J. Periodontol. 78(6), 1136-1145 (2007).
127. Chen M, Towers LN, O'Connor KL: LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am. J. Physiol. Cell Physiol. 292(5), C1927-C1933 (2007).
128. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O: The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl Acad. Sci. USA 103(25), 9643-9648 (2006).
129. Stadler CR, Knyazev P, Bange J, Ullrich A: FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal. 18(6), 783-794 (2006).
130. Kitayama J, Shida D, Sako A et al.: Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6(6), R640-R646 (2004).
131. Liu S, Umezu-Goto M, Murph M et al.: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15(6), 539-550 (2009).
132. Guo R, Kasbohm EA, Arora P et al.: Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147(10), 4883-4892 (2006).
133. Im DS, Heise CE, Harding MA et al.: Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57(4), 753-759 (2000).
134. Hao F, Tan M, Xu X et al.: Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38α. Biochim. Biophys. Acta 1771(7), 883-892 (2007).
135. Lin S, Wang D, Iyer S et al.: The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 136(5), 1711-1720 (2009).
136. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
137. Ozols RF, Bundy BN, Greer BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194-3200 (2003).
138. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(33), 5165-5171 (2007).
139. Hirte HW VL, Fleming GF et al.: A Phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal, or fallopian tube cancer: final results of PMH, Chicago and California consortia trial. Proc. Am. Soc. Clin. Oncol. 26, 5521 (2008).
140. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129-3140 (2008).
141. Murph MM, Liu W, Yu S et al.: Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE 4(5), E5583 (2009).